Compare Anheuser-Busch Inbev SA (BUD) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Intuitive Surgical, Inc. — how do they compare? Anheuser-Busch Inbev SA trades at $79.82 (market cap $153.45B), while Intuitive Surgical, Inc. trades at $390.98 (market cap $134.40B). The key difference: Anheuser-Busch Inbev SA and Intuitive Surgical, Inc. are close in size by market cap, and Anheuser-Busch Inbev SA pays a 1.7% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals.
| BUD | ISRG | |
|---|---|---|
Market Cap | $153.45B | $134.40B |
Sector | Consumer Staples | Health |
52-Week High | $85.09 | $592.85 |
52-Week Low | $57.10 | $379.50 |
Enterprise Value | $214.64B | $129.89B |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.33, down 0.35% with bearish technical signals. The company demonstrates solid fundamentals with consistent earnings beats, 11.9% net margin, and improving cash flow. Recent dividend payment of $1.17 and positive analyst sentiment with 57.8% buy ratings support the investment case. Premiumization strategy and digital expansion drive growth amid changing consumer preferences.
Outlook remains positive with $90.08 consensus price target offering 13.5% upside. Key risks include alcohol moderation trends and competitive pressures. Strong balance sheet with declining debt-to-asset ratio to 33.9% provides financial stability. Revenue growth expected to accelerate to $61B in 2026 with expanding margins.
Intuitive Surgical (ISRG) trades at $407.12, showing minimal daily change. The stock is in a bearish technical trend but maintains strong fundamentals with consistent revenue growth, expanding profit margins, and a history of earnings beats. Recent news highlights near-term headwinds and a significant decline from 52-week highs, yet analyst sentiment remains largely positive, focusing on long-term robotic surgery market penetration.
The outlook balances strong fundamentals against technical weakness. Investment opportunity lies in market leadership and earnings growth potential, but risks include competitive pressures and execution challenges. Wall Street consensus is bullish with a $557.60 price target, suggesting substantial upside if the company navigates current challenges successfully.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
